PA
STRO icon

Perceptive Advisors’s Sutro Biopharma STRO Stock Holding History

Perceptive Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.3M Buy
1,304,846
+589,539
+82% +$18.4M 0.65% 33
2026
Q1 		$17.8M Buy
+715,307
New +$12.9M 0.35% 56

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Perceptive Advisors's STRO Position: Q2 2026 in Review

Perceptive Advisors increased its Sutro Biopharma (STRO) stake by 82% in Q2 2026, buying an estimated $18.4M and bringing the position to 1,304,846 shares worth $43.3M. The position accounts for 0.65% of the portfolio, ranked #33.

Perceptive Advisors first reported a position in STRO in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Perceptive Advisors held 1,304,846 shares of Sutro Biopharma worth $43.3M as of Q2 2026.
  • Perceptive Advisors bought 589,539 Sutro Biopharma shares in Q2 2026, an estimated $18.4M.
  • Sutro Biopharma made up 0.65% of Perceptive Advisors's portfolio in Q2 2026, its #33 holding.
  • Perceptive Advisors first reported a position in Sutro Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.